Our people

Alex Galbraith

Alex Galbraith

Our People

Alex Galbraith

Associate, Patent Attorney

Life Sciences


Our People

Our IP specialists work at all stages of the IP life cycle and provide strategic advice about patent, trade mark and registered designs, as well as any IP-related disputes and legal and commercial requirements.

View the team

News & Insights

We want to keep you up to date with developments in the IP world and let you know what we are up to at Mewburn Ellis.

Learn more

Law & Practice Guide

We believe in making it easy for you to find the information that you want – and you can always contact us if you can’t find what you need

Read our law and practice guides

Alex is a patent attorney working in our life sciences team. He has experience working with both local and international clients, assisting with a range of patent matters such as drafting of patent applications related to antibody-based therapeutics, including bispecific antibodies and antibody-drug conjugates, and prosecution of patent applications before the UKIPO and the EPO.

He also has experience working on large multi-party oppositions and appeals before the EPO relating to antibody-based therapeutics and antibody production methods involving multinational biopharmaceutical clients, as well as assisting with Freedom to Operate and validity opinions.

Areas of Expertise

Biotechnology, with a special interest in:

  • Gene editing, particularly CRISPR-based editing technologies such as base editing and prime editing
  • Cell and gene therapies
  • Antibody-based therapeutics, particularly antibody-drug conjugates and novel antibody formats
  • Cancer therapeutics and biomarkers
  • Antibody production methods


Alex has a BSc degree in Biological Sciences from Durham University where he was awarded the Biological Sciences Prize. He also gained industrial experience working with CRISPR base editing technology within a large pharmaceutical company during his degree. 

Alex joined Mewburn Ellis in 2020 and qualified as a Chartered Patent Attorney in 2024.